Insulet Corporation announced the launch of its Omnipod 5 automated insulin delivery system and the Omnipod Discover patient‑portal platform in the Middle East, specifically in Saudi Arabia, Kuwait, Qatar and the United Arab Emirates.
The Omnipod 5 pod is tubeless, disposable, and can deliver insulin for up to three days. It automatically adjusts insulin delivery every five minutes based on continuous glucose monitoring data, and it is compatible with Dexcom and Abbott FreeStyle Libre CGMs. The Discover platform connects patients, clinicians and pharmacies, streamlining data sharing and care coordination.
Insulet’s strategy relies on a pharmacy‑channel distribution model that supports a subscription‑style, high‑margin business. The new launch extends that model beyond the United States, allowing patients in the Middle East to access the same recurring revenue stream that has driven growth in other markets.
Diabetes prevalence in the Middle East is rising, with high rates of both type 1 and type 2 disease. Historically, tubed pump competitors have had limited penetration in the region, creating an underserved market that Insulet aims to capture with its tubeless design and integrated data platform.
Pat Crannell, Insulet’s Senior Vice President and International General Manager, said, “We’re proud to bring Omnipod 5 to a region where the unmet need is great. These launches build on our momentum as we transform the lives of people with diabetes worldwide.”
The expansion is expected to drive incremental revenue and reinforce Insulet’s strategy of expanding its addressable market beyond the United States, positioning the company to capture a growing share of the Middle Eastern diabetes‑care market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.